Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis. 28415658 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 Biomarker disease BEFREE MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS. 29183007 2018
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.700 GeneticVariation disease BEFREE Investigation of patterns of nodal metastases in BRAF mutant lung cancer. 28625649 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 Biomarker disease BEFREE Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer. 28242811 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 Biomarker disease BEFREE Genetic lesions that activate KRAS account for ∼30% of the 1.6 million annual cases of lung cancer. 28320962 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE Establishment of highly metastatic KRAS mutant lung cancer cell sublines in long-term three-dimensional low attachment cultures. 28786996 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE Recent clinical studies have revealed that sorafenib, a pan-RAF and VEGFR inhibitor, has impressive benefits for KRAS mutant lung cancer patients. 26350096 2017
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.700 Biomarker disease BEFREE One of our predicted biomarker pairs, a mutation in the BRAF gene and upregulated expression of the PIM1 gene, was experimentally validated to benefit from a therapy combining BRAF inhibitor and PIM1 inhibitor in lung cancer. 26916442 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S). 26920031 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. 27055085 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE There are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer. 28492898 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer. 28368426 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE We retrospectively reviewed EGFR and KRAS mutation results of 399 (patients with EGFR mutation test) and 323 patients (patients with KRAS mutation test) diagnosed with lung cancer in Konkuk University Medical Center from 2008 to 2014. 27478332 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE Left-side lung cancer was more common in female patients carrying the KRAS mutation. 26739511 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). 25634006 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer. 26657862 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE Oncogenic KRAS mutations represent the largest genomically defined subset of lung cancer, and are associated with activation of the RAS/RAF/MEK/ERK pathway. 26837474 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE The high frequency of EGFR mutations and low frequency of KRAS mutations in Hispanic populations and different prevalence in lung cancer-related-developing risk factors compared with Caucasian populations, such as the lower frequency of smoking exposure and higher WSE, particularly in women, might explain the prognosis differences between foreign-born-Hispanics, US-born-Hispanics and NHWs. 26358312 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 Biomarker disease BEFREE Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. 26473645 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 Biomarker disease BEFREE KRAS mutations (codons 12/13) were found to be a biomarker of radiosensitization by midostaurin in lung cancer, which was pronounced under conditions that enriched for stem cell-like cells. 25667133 2016
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.700 AlteredExpression disease BEFREE Recent evidence shows that BRAF-activated non-coding RNA (BANCR) acts as a critical role in the proliferation and metastasis in malignant melanoma and lung cancer; however, little is known about the significance of lncRNA BANCR in retinoblastoma. 25894373 2016
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.700 Biomarker disease BEFREE Jointly, our results suggest a potential role of the novel BRAF fusion in lung cancer development and therapy. 25985019 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE KRAS mutations commonly occurred with loss in TP53 and there was significant loss of BRCA1 and NF1 among male patients with lung cancer. 26880400 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE There's a need for developing target therapies for KRAS mutant lung cancer and other tumors. 26840022 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD. 26316738 2016